Scribe Therapeutics (NASDAQ:SCTX) Releases Quarterly Earnings Results, Beats Estimates By $2.36 EPS

Scribe Therapeutics (NASDAQ:SCTX) posted its quarterly earnings data on Wednesday. The company reported ($3.84) EPS for the quarter, topping the consensus estimate of ($6.20) by $2.36, Zacks reports. The firm had revenue of $1.92 million for the quarter, compared to the consensus estimate of $3.10 million.

Scribe Therapeutics Stock Down 0.3%

Shares of SCTX stock opened at $30.81 on Friday. Scribe Therapeutics has a 1 year low of $17.31 and a 1 year high of $39.60.

Insider Transactions at Scribe Therapeutics

In other news, Director Carl Gordon purchased 1,000,000 shares of the company’s stock in a transaction on Monday, July 27th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the director owned 1,348,825 shares in the company, valued at $20,232,375. This trade represents a 286.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David Parrot acquired 2,666 shares of the business’s stock in a transaction dated Thursday, July 23rd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the completion of the acquisition, the chief financial officer directly owned 1,333 shares of the company’s stock, valued at approximately $19,995. This trade represents a -200.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 3,727,237 shares of company stock worth $56,291,746.

Analysts Set New Price Targets

SCTX has been the subject of several recent analyst reports. Zacks Research upgraded shares of Scribe Therapeutics to a “hold” rating in a research note on Tuesday. Leerink Partners initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price objective for the company. HC Wainwright initiated coverage on Scribe Therapeutics in a research note on Monday. They set a “buy” rating and a $60.00 target price on the stock. Wells Fargo & Company began coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.

Key Scribe Therapeutics News

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Scribe initiated the first-in-human Phase 1 trial of STX-1150, an experimental LDL-cholesterol-lowering therapy designed to provide long-lasting effects without permanent genetic changes. The trial represents a major clinical-development milestone. Scribe starts Phase 1 trial for cholesterol drug STX-1150
• Positive Sentiment: The company reported a second-quarter loss of $3.84 per share, narrower than the $6.20 analyst consensus, primarily because of lower expenses. Scribe Reports Narrower Loss in Q2 Due to Lower Expenses
• Positive Sentiment: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance its STX-1200 and STX-1400 programs. In addition, its July IPO and private placement with Sanofi generated approximately $155.5 million in gross proceeds, extending expected funding into the first half of 2029. Scribe Therapeutics Second Quarter 2026 Results and Corporate Highlights
• Positive Sentiment: HC Wainwright began coverage with a Buy rating and a $60 price target, well above the stock’s recent trading level, providing a bullish Wall Street view. HC Wainwright Begins Coverage on Scribe Therapeutics
• Neutral Sentiment: Zacks Research upgraded Scribe to Hold, suggesting a more cautious near-term stance despite the company’s development progress.
• Negative Sentiment: Quarterly revenue was only $1.92 million, below the $3.10 million analyst expectation, while Scribe remains unprofitable. Analysts expect a full-year loss of approximately $6.72 per share, underscoring substantial ongoing cash-burn and execution risk.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.